Tangshan Central Hospital Trials

Tangshan Central Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Li, Jun

HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting

640

RoW

Tenofovir Amibufenamide（TMF）, HS-10234

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Hepatitis B, Chronic

06/24

09/29

NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed

248

RoW

Hydronidone capsules, F351, The placebo capsules, N

Beijing Continent Pharmaceutical Co, Ltd.

Liver Fibrosis

10/24

NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting

1000

Europe, Canada, US, RoW

IVA337, Lanifibranor, Placebo

Inventiva Pharma

NASH - Nonalcoholic Steatohepatitis

09/25

09/26

CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

02/24

10/27

NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting

248

RoW

Hydronidone capsules, F351, The placebo capsules, N

Beijing Continent Pharmaceutical Co, Ltd.

Liver Fibrosis

06/28

10/28

NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Recruiting

2/3

520

RoW

HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo

Sunshine Lake Pharma Co., Ltd.

Chronic HCV Infection

04/23

NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

Completed

228

RoW

Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group

Tasly Pharmaceutical Group Co., Ltd

Chronic Heart Failure With Reduced Ejection Fraction

11/24

LUMMICAR STUDY 1, NCT03975907: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting

1/2

121

RoW

CAR-BCMA T Cells

CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University

Multiple Myeloma

12/24

12/25

NCT04384393: Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

Recruiting

RoW

ThisCART19 cells

Fundamenta Therapeutics, Ltd., Anhui Provincial Hospital

B Cell Malignancy

11/22

10/23

NCT05127135: Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

Recruiting

RoW

ThisCART7 cells

Fundamenta Therapeutics, Ltd., The First Affiliated Hospital of University of Science and Technology of China

T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma

01/23

12/23

NCT05098197: Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers

Recruiting

RoW

Tumor Infiltrating Lymphocyte

Shanghai Juncell Therapeutics, Shanghai 10th People's Hospital

Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy, Advanced Pancreatic Cancers

09/26

iVEST, NCT04748965: Imaging-Guided Vessel Sizing in the Tibial Arteries

Completed

N/A

Digital Subtraction Angiography

University Hospitals Cleveland Medical Center, Abbott Medical Devices

Peripheral Artery Disease, Critical Limb Ischemia

06/24

PEERLESS, NCT05111613: The Study

Completed

N/A

692

Europe, US

Catheter-Directed Thrombolysis, FlowTriever System

Inari Medical

Pulmonary Embolism, Pulmonary Thrombo-embolism

03/24

04/24

Promote, NCT05797714: The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

Active, not recruiting

N/A

200

RoW

Tenofovir Amibufenamide（TMF）, HengMu

Ruijin Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.

HBV Infection, Chronic Hepatitis b

06/24

04/26

ASCENT, NCT06246045: Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation

Not yet recruiting

N/A

390

Walking test

University Hospitals Cleveland Medical Center, Inari Medical

Pulmonary Embolism Subacute Massive

01/26

NCT05907564: Aventus Thrombectomy System Pulmonary Embolism Clinical Study

Recruiting

N/A

120

Thrombectomy

Inquis Medical, Inc.

Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases

03/25

ELEGANCE, NCT04674969: Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Recruiting

N/A

5000

Europe, Canada, US, RoW

Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.

Boston Scientific Corporation

Peripheral Vascular Diseases

01/28

C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Recruiting

N/A

300

RoW

Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir

Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd

Hepatitis C, Chronic

07/21

08/21

Liao, Wang

NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting

8250

RoW

Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy

Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.

Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases

04/25

Xing, Jianong

NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting

8250

RoW

Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy

Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.

04/25

Zhang, Tianhua

NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting

8250

RoW

Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy

Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.

04/25



	Diseases Companies Products Productz Mechanisms of Action Sites